Endocrine Abstracts

Aim: To explore if MR-proANP is associated with cardio-metabolic risk factors in patients with med type 2 diabetes mellitus (T2D) and non-diabetic controls.

Methods: MR-proANP was analyzed in 761 middle-aged (54–66years) patients with type 2 diabetes and 184 non-diabetic controls and related cardio-metabolic conventional risk factors as age, sex, previous cardiovascular diseases (atrial fibrillation, myocardial infraction), glucose, LDL cholesterol, mean systolic blood pressure, active smoking, BMI, left ventricular mass index (LVMI), toe pressure index (TBI).

Results: Lower levels of MR-proANP were found in patients with T2D compared to non-diabetic controls (73±38.5 vs. 80.3±31.2 pmol/l, P=0.03). In T2D and non-diabetes group MR-proANP was positively correlated to age (r=0.2, P<0.001 and r=0.4, P<0.001, respectively) and LVMI (r=0.1, P=0.003 and r=0.2, P=0.03, respectively) and negatively to blood glucose (r=−0.7, P=0.05 and r=−0.1, P=0.03, respectively) and LDL-cholesterol (r=−0.01, P=0.6 and r=−0.1, P=0.02 respectively). For T2D patients linear regression analysis adjusted model for cardio-metabolic risk factors MR-proANP showed an significant association to gender (B=0.04, 95% CI 0.02–0.06, P<0.001), age (B=0.009, 95% CI 0.005–0.01, P<0.001), previous atrial fibrillation (B=0.09, 95% CI 0.009–0.1, P=0.03), BMI (B=0.005, 95% CI 0.001–0.009, P=0.03), systolic blood pressure (B=0.001, 95% CI 0.001–0.001, P=0.02), active smoking (B=0.04, 95% CI 0.01–0.07, P=0.001) and abdominal circumference (B=0.002, 95% CI 0.001–0.004, P=0.005). For non-diabetic controls MR-proANP was associated to gender (B=0.06, 95% CI 0.01–0.1, P=0.1), age (B=0.004, 95% CI 0.001–0.008, P=0.03) and abdominal circumference (B=0.005, 95% CI 0.001–0.01, P=0.03).

Conclusion: Lower levels of MR-proANP in T2D compared to non-diabetic controls showed significant association with cardio-metabolic risk factors. Our results suggest that ANP could have metabolic actions and may be implication in the pathophysiology of T2D.